"If radiation was a drug that could improve survival in the metastatic setting like that it would be millions and millions of dollars." -- James B. Yu, of Yale Cancer Center, discussing aggressive use of stereotactic body radiation therapy in oligometastatic cancer.
More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.
This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups. ACR 2018 highlights for me included:
As expected, this year’s ACR meeting saw an upswing in the number of abstracts on immune related adverse events from checkpoint inhibitor therapy compared to last year.
A very small study presented at ACR18 looking at tocilizumab monotherapy in patients with a new diagnosis of giant cell arteritis has nevertheless given hope to the tantalising idea that some GCA patients might achieve drug-free remission without steroids, although broader data are requ
A number of abstracts at this year’s ACR in Chicago highlighted issues around pregnancy and contraception advice in routine clinical practice.
Audio Highlights and Interviews from Day 3 at the ACR 2018 meeting LISTEN HERE
Rheumatologists tend to be a conservative bunch of people. We’re law abiding and we (mostly) follow guidelines. Which is fine when they are in the best interests of our patients, but what do we do when we fundamentally disagree?
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
